Abstract The cancer stem cell hypothesis postulates that a single stem-like cancer cell is able to produce all cancer cell types found in a tumor. These cells are also thought to be the causative agents of relapse following therapy. In order to confirm the importance of cancer stem cells in tumor formation and patient prognosis, their role in prostate cancer must be comprehensively studied. This review describes current methods and markers for isolating and characterizing prostate cancer stem cells, including assays for self-renewal, multipotency and resistance to therapy. In particular the advantages and limitations of these approaches are analyzed. The review will also examine novel methods for studying the lineage of cancer stem cells in vivo using transgenic mouse models. These lineage tracing approaches have significant advantages and, if a number of challenges can be addressed, offer great potential for understanding the significance of cancer stem cells in human prostate cancer.
Introduction
The cancer stem cell (CSC) hypothesis postulates that tumour masses may arise from a single cancer cell with stemlike characteristics. These CSCs are thought capable of selfrenewal and differentiation to regenerate the tumour mass and all tumor cell types found within. Such cancer cells were first identified in leukemia in the 1990s [1, 2] followed by discoveries in breast cancer [3] , and subsequently in other solid tumors [4, 5] including prostate cancer [6] . CSCs appear to be rare within tumors as only a small proportion of all prostate cancer cells are able to reliably form large clones in vitro [6] and xenograft prostate tumors in vivo [7, 8] . Another feature attributable to cancer stem cells is their resistance to conventional treatment regimens, particularly chemotherapy [9] and radiotherapy [10] . The continued survival and self-renewal of CSCs is potentially an enticing explanation for relapse, metastasis and therapy failure in prostate cancer. A concerted effort is underway to isolate, characterize and target this critical cell population in order to produce more effective therapies.
In addition to the excitement surrounding CSCs there is also a great deal of controversy concerning their study. The putative CSC subpopulations isolated from prostate cancer cell lines and patient tumors vary considerably in their expression patterns and phenotypes. This heterogeneity complicates the identification of distinct cancer stem cell markers and impedes efforts to target the cells therapeutically. The hierarchy of cell fate in the normal prostate is also incompletely understood. For instance, the origin and ontogeny of normal adult prostate stem cells remains controversial [11] , with some suggesting that there is a common progenitor of basal and luminal cells [12, 13] ; that basal cells differentiate to produce luminal epithelium [13] ; or that basal and luminal cells have separate progenitors to maintain their lineages [14] . The origins of prostate cancer are also poorly understood, and there is evidence that prostate cancer may arise from both basal cells [15] and luminal cells [16] in both murine models and in humans. Likewise, it is unclear whether cancer stem cells are transformed stem cells; or differentiated cancer cells that reactivate stem cell-associated self-renewal programs [11] . Therefore, methods to probe both stem cell phenotypes and cancer cell fate are crucial to identify and characterize prostate cancer stem cells.
This review will focus on the markers and methods used to characterize cancer stem cells in the prostate (summarized in Fig. 1 ). Methods to measure self-renewal, multipotency and resistance to therapy will be covered and the advantages and limitations of these methods examined. We will also consider recent novel approaches using in vivo lineage tracing that are beginning to be applied to the study of prostate cancer stem cells. These offer significant advantages over traditional methods, but there are still challenges that need to be overcome in the search for the ideal model to study prostate CSCs.
Biomarkers for Prostate Cancer Stem Cells
In this context, biomarkers are RNAs or proteins whose expression levels, either alone or in combination with other proteins, indicate the presence of cancer stem cells. Although there are many potential CSC markers, this review will cover some of the frequently used markers. Cell surface biomarkers are especially versatile because they can often be used to purify and analyze cancer stem cell populations by fluorescence-activated cell sorting (FACS) or magneticactivated cell sorting (MACS). Expression of markers can also be analyzed by immunohistochemistry and reversetranscriptase polymerase chain reaction (RT-PCR), often in combination with the above cell sorting methods.
Cell Surface Markers
Cell surface markers may be used to isolate cancer stem cells from a cell line or dissociated primary tumor. CD44 is a hyaluronan-binding cell-surface glycoprotein that is often used to purify cancer stem cells by FACS. CD44 has recently been the basis for the isolation of putative cancer stem cells in many tissues, including the prostate. When characterizing prostate cancer stem cells, CD44 is often complemented by a variety of other markers (Table 1) .
CD44 and other cancer stem cell markers also help to verify that isolated populations are likely to be cancer stem cells. CD44 was found to be highly expressed in prostatospheres derived from four different prostate cancer cell lines [17] . CD44 + /CD24 -purified DU145 [18] and LNCaP [8] prostate cancer cell lines form prostatospheres (see "Self-Renewal") with the potential to differentiate. Stem-like PSA -/low cells sorted for the antigenic profile ALDH + /CD44 + /α 2 β 1 + had higher tumorigenicity than ALDH -/CD44 -/α 2 β 1 -cells and PSA -cells, with ten cells being sufficient to induce a xenograft tumor in NOD/SCID mice [19] . Similarly, tumorigenic prostate cancer stem cells, comprising 0.1 % of the total cells, have been isolated from primary human prostate tumors using the antigenic profile CD44 + /α 2 β 1 high /CD133 + [6] . Immunofluorescent staining may be employed to investigate the expression of markers such as CD44, CD24 and α 2 β 1 integrin for confirmation of stem-like phenotypes in prostatospheres, such as those generated from the DU145 cell line [20] . Prostatosphere cells Fig. 1 [15] . Similarly in head and neck squamous cell carcinoma, CD44
-cells had CSC-like properties despite its use as a marker for CSCs [21] . However, it is clear that CD44 and other cancer stem cell markers may be more useful when combined with other markers of interest.
Markers of Resistance
The ABC transporter ABCG2 can be used to identify populations of putative stem cells in many tissues, and is thought to be the molecular basis for the Hoechst side population, which is commonly used to select for chemoresistant cancer stem-like cells from many tumor types [22, 23] (see "Resistance to Therapy"). ABCG2 may be involved in resistance to therapy, both from chemotherapy [23] and from androgen deprivation [24] . However, as with many putative CSC markers the use of ABCG2 remains controversial. ABCG2 -and ABCG2 + prostate cancer cell line subpopulations can interconvert and are similarly tumorigenic, which makes it difficult to isolate distinct populations in vitro [25] . Patrawala [26] , suggesting that its use as a marker may be improved when used in tandem with other markers.
Markers of Pluripotency
Many embryonic stem (ES) cell pluripotency factors, such as Nanog, Oct4 and Sox2, are known to be expressed in both adult stem cells and CSCs, and an embryonic stem cell gene expression signature was found to identify poorly differentiated tumors from several types of human cancer [27] . Such factors may be useful for the identification of stem-like cells in prostate cancer, as they underpin important cancer stem cell phenotypes such as self-renewal. DU145 prostatosphere cells express the ES pluripotency factors Nanog, Oct4 and Sox2 [20] , as do immortalised prostate cancer epithelial cell cultures [28] . Expression of Nanog and Oct4 is also enriched in primary tumors of gleason grade 5, an indicator of poor prognosis [29] . In xenograft prostate tumors, rare CD44 + stem-like cells have also been found to express Nanog [30] . This evidence suggests that the presence of stem cell markers is a common feature of poor-prognosis tumors. However, Sox2 expression was recently found to be regulated by signaling through the Androgen Receptor [31] , but was not associated with a CSC population. In addition both Oct4 [32] and Nanog [33, 34] have multiple pseudogenes and splice variants which could have differing importance to prostate cancer stem cells and complicate analysis. Therefore, caution should be used when treating expression of these markers in isolation as evidence of cancer stem cells. [30] . Conversely, another group observed upregulation of basal-specific cytokeratin 5 in DuCaP cell lines under androgen deprivation, but could not detect expression of the neuroendocrine marker Nestin [24] . However, when comparing expression profiles of castration resistant and non-resistant human prostate tumors by microarray, the group found that both basal (Cytokeratin-5) and neuroendocrine (Nestin) markers were upregulated along with the putative cancer stem cell markers CD44 and c-Kit. Immortalised prostate cancer epithelial cells generated by Gu et al. [28] also express Nestin along with embryonic stem cell markers, consistent with a neuroendocrine-like CSC phenotype. The variability of expression patterns in multiple models of prostate cancer suggests that cancer stem cells may be more than one distinct subpopulation. It could also be a reflection of the phenotypic plasticity of cancer stem cells that has been recently indicated in vitro and in vivo [25, 35, 36] . Regardless, determining the cell type of origin, and the heterogeneity thereof, is important in order to further establish the identity of prostate cancer stem cells. Overall, biomarkers are useful for probing all aspects of cancer stem cells but given the apparent heterogeneous nature of cancer stem cells, no single marker is ideal and combinations of markers should be analyzed in tandem for specific phenotypic characterization. However, given the plasticity and diversity of CSC-associated antigenic profiles it is unlikely that a single profile, however specific, will be able to capture all relevant CSC subpopulations. Therefore, to get a full picture multiple antigenic profiles may be needed to capture different populations of potential CSCs. In addition these markers should be used in combination with functional assays which are considered below.
Self-Renewal
A defining property of both stem cells and cancer stem cells is their self-renewal capacity. There are two main types of in vitro assay used to probe self-renewal in isolated cell populations: clonogenicity assays and sphere formation assays. Both assays involve the culture of isolated cells in conditions that preferentially maintain stem cells, thus selecting for those cancer cells with more stem-like properties in vitro. They may also be considered proliferation assays, as self-renewal and proliferation are not distinct in this context. As most cancer cells are expected to have some self-renewal capacity, these assays are comparative in nature, and rely on the isolated CSCs being significantly different from a control population of cells for a tested phenotype. These in vitro assays are not standalone tests for cancer stem cells and should be used in conjunction with other functional assays and marker analyses.
The clonogenicity assay involves seeding a single cell or a small number of cells onto culture plates, and monitoring colony formation after a defined time period. This assay is based on the assumption that small titres of cells will only form large colonies if they have the ability to self-renew [37] . The number of colonies present is then treated as a correlate of self-renewal capacity. This assay can be done serially with a single cultured cell, making it possible to further demonstrate a clone's self-renewal capacity over multiple passages in vitro [6] . There are some disadvantages with this assay; one being that an arbitrary threshold must be assigned to determine which colonies are too small to count. More significantly the assay may not provide a complete representation of self-renewal capacity in vivo.
A variation of the clonogenicity assay can provide more information about self-renewal capacity by classifying the colonies into categories. When prostate cancer cells are cultured at single cell titres, the resulting colonies can be divided into: holoclones, meroclones and paraclones [38] . Holoclones are small, dense colonies with high self-renewal capacity; paraclones are large with reduced cell density and low self-renewal capacity; and meroclones have an intermediate phenotype. Holoclones can give rise to both meroclones and paraclones, whereas meroclones can only give rise to paraclones, thus demonstrating a hierarchical lineage structure characteristic of stem cell differentiation. Holoclones may contain a population of CSCs, as shown by the ability of PC-3 cells to form xenograft tumors at extremely low titre and their expression of the CSC-associated markers CD44 and α 2 β 1 integrin [38] . Sorting for a stem-like fraction of ALDH high PC-3 cells (see "Resistance to Therapy") increases the frequency of holoclone formation [39] , although there is considerable phenotypic plasticity in ALDH expression within these cells. This plasticity is a recurring phenomenon in CSCs and multiple characterization steps should be employed in order to obtain robust conclusions from the data.
Another important tool is the sphere formation assay. The method was originally used to study adult neural stem cells in vitro [40] and has now been applied to isolate CSCs. Low adherence culture in defined serum-free medium produces clonal multicellular spheroid aggregates called tumorspheres (prostatospheres in prostate cancer), which are enriched for cells displaying cancer stem cell phenotypes. Anchorageindependent growth is a malignant phenotype in itself, suggesting that isolated CSCs are selected by their innately malignant phenotypes. This method is now widely-used for the enrichment of cancer stem cells from many types of cancer, including prostate cancer. The assay is versatile, and may be used in prostate cancer cell lines [17, 41, 42] and explanted primary prostate tumor tissue [26, [42] [43] [44] , or to further characterize cells isolated by other methods [45] [46] [47] . Prostatospheres form at low efficiency, originating from a small fraction of the tumor cell population [43] and can be serially cultured [39, 43, 44, 48, 49] , allowing for additional probing of self-renewal capacity and further enrichment of CSCs. Prostatosphere cells tend to possess CSC-associated phenotypes, such as self-renewal in long-term culture and expression of putative cancer stem cell markers such as CD44 and integrin α 2 β 1 [20, 50] . However, sphere formation may not always select for cancer stem cells in vitro. α2β1 + prostate cancer stem cells isolated from prostate xenograft tumors had high clonogenicity and sphere-forming capacity, but did not have the high tumorigenicity in xenografts expected of cancer stem cells [51] . Similarly, when Matilainen et al. [52] attempted to isolate breast cancer stem cells using this method, the result was an unexpected reduction in CSCassociated gene expression and a loss of metastatic phenotypes. Prostatospheres may not consist purely of CSCs, but contain some differentiated and dying cells [18] , and there are concerns that sphere generation is not being sufficiently validated-for example, to ensure that sphere formation is a result of cell proliferation and not cell aggregation [53] . These conclusions highlight the need to verify all findings in vivo before any conclusions are made.
A well-established test for in vivo self-renewal comes from xenograft transplantation assays. Low titres of CSCs isolated from cell lines [7] or from dissociated primary [7] and xenograft [43] prostate tumors are injected into immunodeficient mice. Cells that reliably form primary tumors [7, 41, 43, 54, 55] or metastases [7] at this limiting dilution are proposed to have a cancer stem cell phenotype. To provide more evidence for the CSC identity of the cells, xenograft tumor formation assays can be done serially using purified dissociated cells from xenograft tumors [54] . The ability to serially generate tumors at limiting dilution is an indicator of self-renewal in vivo. Large tumor size and high tumor-forming capacity are indicators of an aggressive subpopulation of cells in vivo. Toivanen et al. have found that the addition of mouse mesenchymal tissue to human primary tumor xenografts improves tumorforming efficiency [55] , demonstrating a contribution of the mesenchyme to tumor formation. Such chimeric xenografts appear to recapitulate a human cancer phenotype, but whether CSCs retain the original behaviours and expression profiles under these conditions must be further investigated. Although xenografts do not fully represent tumor formation in situ, they are a versatile and commonly used model for tumorigenesis and self-renewal in vivo. In fact this approach was perhaps the gold standard model for studying CSCs, until the advent of in vivo lineage tracing approaches, which are considered below.
Multipotency
Another defining characteristic of cancer and normal stem cells is their ability to differentiate. Differentiation can be induced in vitro by culturing cells in Matrigel™ (BD Biosciences), and multipotent prostate cancer cells may produce glandular structures that recapitulate prostate cancer architecture in vivo [28] . Alternatively, CSCs may differentiate in standard mammalian cell culture with added serum [6, 8] , which can be verified by the loss of expression of stem cell markers, and increased expression of differentiated cell markers.
Quantitative matrigel assays have been developed specifically for the study of prostate stem cell differentiation in vivo [56] . Matrigel induces differentiation, causing putative prostate stem cells to form glandular structures. The group injected a single cell suspension of digested murine prostate in matrigel into the flank of BALB/c mice in order to assay for prostate reconstitution in vivo. Different proportions of EGFP-labeled transgenic mouse prostate cells and unlabeled mouse prostate cells were used to trace their respective contribution to reforming individual prostate ducts. No mosaicism was observed in the ducts, allowing them to propose that single prostate stem/progenitor cells are able to reconstitute entire prostate ducts, thus demonstrating the self-renewal and differentiation potential of the cells. In a similar tissue recombination assay, prostate cancer cells can be recombined with inductive rat urogenital mesenchyme and grafted under the renal capsule of immunodeficient mice. Gland-like structures form that recapitulate the structures and cell types found in the original prostate [57] or prostate tumor [28] , thus demonstrating a stem-like capacity for differentiation. The renal graft model can also be used to assay for malignant transformation capacity, by recombining selected prostate epithelial cells with human cancerassociated fibroblasts (CAFs) [15, 58] . Although the assay is reproducible within individual CAF populations, different CAF isolates stimulate tumorigenesis to differing degrees in this model [58] , which is a source of experimental variability. In addition, CAFs are not capable of initiating tumor formation in normal murine prostate epithelium [58] , but instead appear to accelerate tumor progression in already initiated cells. However, the main advantage of these xenograft models is that the supporting stroma can be altered as required in order to suit experimental needs. These approaches are beginning to elucidate the cellular origin of prostate cancer and the role that stromal interactions play in it.
Resistance to Therapy
The segregation of cancer stem cells from a cell population may be achieved by selecting for their resistance to standard cancer treatments. This is based on the observation that cancer stem cell populations tend to survive exposure to chemotherapeutic agents in vitro [9] . Similarly, prostate CSCs have been proposed to be resistant to radiation [41] and androgen withdrawal [30] . If a resistant cancer stem cell population exists within prostate cancer then it could contribute to relapse from multiple treatments and is thus an enticing therapeutic target worthy of further analysis. Where possible, all aspects of therapeutic resistance must be characterized.
Prostate CSCs and Castration Resistance
Androgen deprivation is commonly used to treat metastatic prostate cancer, under which the majority of cancer cells will die, producing a remission. However, castration resistance inevitably follows in the period of months to years, resulting in relapse and metastasis. In an androgen-sensitive human xenograft model, Germann et al. have recently identified subpopulations of cancer cells that repopulate the tumor following a cycle of androgen deprivation and replacement [30] , implying a potential role for cancer stem cells in the development of castration-resistant prostate cancer. Miki et al. have shown that inducing differentiation in culture can cause stem-like AR -prostatosphere cells to become AR + [42] , suggesting that lack of AR expression may be an important cancer stem cell phenotype. Therefore, testing for castration resistance and AR expression are important characterization steps for any prostate cancer stem cell population.
Prostate CSCs and Chemoresistance
One method of isolating cells that are potentially chemoresistant and stem-like is the well-established Hoechst Side Population sorting protocol. In this method, live cells are stained with the dye Hoechst 33342. Cells stained with this dye fluoresce at blue and red wavelengths that can be detected by Flow Cytometry. In contrast, stem-like cells efflux this dye and fluoresce poorly in channels, allowing for their separation from the rest of the population by cell sorting [23] , and further characterization. The ability to efflux cytotoxic Hoechst dye is linked to the expression of ABC transporters such as ABCG2 [22] , which may also be involved in the efflux of chemotherapeutic drugs [23] . Because of this, the method is able to identify chemoresistant stem-like cancer cells without prior knowledge of CSC expression profiles in the tumour type [59] . Side population cells taken from normal human prostate generated more numerous prostate ducts with greater efficiency than non-side population cells in a renal graft assay [60] , with as little as 50 side-population cells producing successful grafts. The success of such low cell titres shows that the side population is a viable method for isolating stem-like cells from human prostate samples. One disadvantage of this approach is that the Hoechst dye is cytotoxic, so cells may not be amenable for further analysis.
Enzymes of the Aldehyde Dehydrogenase (ALDH) group are associated with poor prognosis in a number of cancers [61] . Some aldehyde dehydrogenases catalyse the biosynthesis of retinoic acid, which is an important molecule involved in differentiation [61] . They also participate in aldehyde and alcohol metabolism. Thus, ALDH enzymes may be functionally involved in self-renewal and resistance to alkylating agents such as cyclophosphamide [62] . In the presence of the dye ALDEFLUOR® (STEMCELL Technologies), stem-like cells with high total ALDH activity fluoresce green and can be sorted by flow cytometry. This method successfully isolates cancer stem cells from several human cancer types [59, 61, 63, 64] including prostate cancer cell lines [37, 39] . ALDH1A1 and other stem cell markers are upregulated in castration resistant prostate cancer compared to noncastrated metastatic disease [24] , suggesting a role for ALDH1A1 in the response to androgen deprivation. Indeed, high ALDH1A1 expression in prostate cancer specimens has been associated with cancer stem-like phenotypes, higher gleason scores and stages, as well as a poor prognosis [54] .
In cell culture experiments, there is the additional option of selecting for chemoresistant cells directly by exposure to a chemotherapeutic agent such as Docetaxel [65] . Isolation using this method means that clinically relevant cell populations may be identified, allowing for investigation into the mechanisms of therapy resistance in castration-resistant prostate cancer. This method has recently identified undifferentiated, HLA -and cytokeratin negative DU145 and 22Rv1 cells that express elevated levels of notch and hedgehog signaling components. Mice carrying DU145 and 22Rv1 xenografts that were treated with Notch and Hedgehog inhibitors demonstrated a reduction in this cell population, suggesting that they may be targeted therapeutically. These cells were also detected in primary and metastatic human prostate tumors. This highlights Notch and Hedgehog signalling as potentially important in therapy resistance of cancer stem cells. Selection for resistance to therapeutic agents can thus reveal novel markers and provide a wealth of information for translational studies.
Prostate CSCs and Radiation Resistance
Some isolated cancer stem cells show resistance to ionizing radiation treatment. Cancer stem cells have been found to be radiation resistant in breast cancer cell lines [66, 67] and glioblastoma [68] . Currently this phenotype has not been widely characterized in prostate cancer stem cells. In the two prostate cancer cell lines that have been investigated, the radiation responses are variable [41] , with LNCaP CSCs showing increased survival compared to total cells, and DU145 CSCs showing no difference. Although this work suggests a role for prostate CSCs in long term recovery from radiation, the mechanisms for this resistance are unknown. Therefore, more work is required to determine whether radiation resistance is a distinguishing characteristic of prostate cancer stem cells.
Novel Approaches In Vivo
Lineage tracing has recently been used to explore the nature of cancer stem cells in vivo. Lineage tracing is a crucial method for demonstrating the ability of a cell to give rise to progeny of different cell types and, when combined with mouse models of cancer, provides a powerful tool to study CSCs in a representative model of carcinogenesis.
Transgenic mouse models have the benefit of being more representive of carcinogenesis, as transformed cells can be investigated in situ, as opposed to xenograft models where the tumor must be studied in a foreign tissue microenvironment that has been disrupted. A comprehensive lineage tracing study by Wang et al. [13] employed lineage tracing to study stem cells in the murine prostate and prostate cancer. These mice expressed a tamoxifen-inducible Crerecombinase under the control of a CK5 promoter. Upon administration of low doses of tamoxifen recombination occurs, causing small numbers of basal cells to express YFP under the control of a CK5 promoter. This allows cell fate to be analysed at a single cell resolution. Using this method, they showed that some bipotential basal cells are capable of giving rise to luminal cells during repeated cycles of prostate regression and regeneration, as well as during normal prostate homeostasis. Using Pten flox/flox mice in this lineage tracing system, they were able to induce basal and luminal-derived prostate cancers: a finding that has been previously observed in similar lineage tracing studies of the murine prostate [14] . Although these studies do not elucidate the exact lineage relationships underlying prostate cancer, they show that basal and luminal cells can act as targets of cellular transformation. Importantly, their results suggest that the cell type of origin may influence the latency and aggressiveness of the tumor, and potentially impact on clinical outcome of prostate cancer patients. Furthermore, they demonstrated that the progenitor cells were much more abundant in prostatospheres and renal grafts grown in vitro than in the transgenic prostate in situ. These findings exemplify the importance of high-quality in vivo models for the study of prostate cancer stem cells.
Lineage tracing can be further refined to resolve the changes of fate that occur throughout cancer development.
Schepers et al. traced Lgr5
+ intestinal adenoma stem cells in Apc-null mice [69] , using a tamoxifen-inducible multicolour Cre reporter system that allowed them to follow the clonal development of each adenoma from single adenoma stem cells. Recombination was then induced a second time to follow the dynamics of adenoma stem cell proliferation, dubbed lineage re-tracing. The re-tracing revealed that intestinal adenoma stem cells are associated with adenoma Paneth cells, as in the normal intestinal crypt, along with assumed transit-amplifying cells. Re-tracing thus allows for the observation of cancer stem cells in their resident niches, and might also enable the study of phenotypic plasticity in cancer stem cells in vivo. This technique has yet to be utilized in the study of prostate cancer.
Sophisticated lineage tracing analyses such as these allow for the study of cancer cell population dynamics to be studied at the level of single cancer stem cells, allowing the existence of cancer stem cells to be demonstrated in well-characterised in vivo models of a cancer. The approaches also have the advantage of interfering minimally with tumor development, eliminating potential artifacts caused by growing tumors in heterotopic positions or in vitro.
Hopefully, lineage tracing in vivo will become the gold standard for demonstrating the existence of cancer stem cells and validating cancer stem cell markers in the prostate. Encouragingly, transgenic mouse models have been successfully employed to trace the lineages of both castrationresistant luminal 'CARNs' [70] and basal cells in the murine prostate and prostate cancer [13] . Lineage tracing studies in the prostate are gradually discerning the cells of origin in prostate cancer and the nature of stem cells in the prostate. However, there are currently limitations to this approach. Mice do not spontaneously develop benign hyperplasia or prostate cancer and require transforming agents or genetic manipulation (such as deletion of Pten) to stimulate the tumorigenesis [71] . There are also some discrepancies between human and transgenic murine prostate cancers. For example, murine models of prostate cancer are very unlikely to undergo metastasis to bone, which is a common feature of the human disease [72] . Anatomical dissimilarity between murine and human prostates is an additional obstacle, as it has been previously shown that transgenic murine models of prostate cancer can vary in phenotype between prostate lobes [14] . Nevertheless, transgenic mouse models are superior to xenografts for modeling the early stages of prostate cancer and are highly likely to facilitate significant future advances.
The ideal method for identifying cancer stem cells would allow for the examination of cancer stem cells in real time as the tumor develops. Non-invasive imaging methods allow for live tumor imaging and thus provide a wealth of data that would not be available through conventional marker analyses. Fluorescent imaging of the putative CSC marker CD133 has been achieved in subcutaneous xenograft tumors [73] , using intravenous administration of fluorescently labeled anti-CD133 antibodies. When implanted subcutaneously, bioluminescent imaging of Balb/c mice has also successfully detected single luciferase-expressing cancer cells (74). There is the potential to adapt this for imaging of cancer stem cells, where detecting small numbers of cells is crucial. Imaging of deeper tissues is complicated by light scattering, which may limit its usefulness for live imaging of prostate cancer stem cells. However, the group were able to detect micrometastases, which demonstrates the ability of the technique to image at least some deep tissues. If this could be improved then the potential to combine single cell in vivo lineage analysis and live imaging offers great potential for future analysis of CSCs.
Conclusion
Cancer stem cells in the prostate are still poorly understood despite concerted efforts to identify and characterise them. There are established prostate cancer stem cell expression profiles, but heterogeneity and phenotypic plasticity hinder the use of a defined panel of markers in this manner. There are also well established in vitro and in vivo xenograft methods that can be extremely useful in the study cancer stem cells. However, these are not without limitations and it is perhaps the advent of in vivo lineage tracing methods which provides the most exciting opportunity to characterize prostate cancer stem cells in ever more innovative ways.
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